{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tipranavir",
    "query": {
      "intervention": "Tipranavir"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tipranavir&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T10:35:01.280Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00352066",
      "title": "Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "apricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avexa",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2006-07",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2011-06-23",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00352066"
    },
    {
      "nct_id": "NCT00735072",
      "title": "Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2008-09",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Stanford, California • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00735072"
    },
    {
      "nct_id": "NCT01232361",
      "title": "IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ADHD",
        "HIV"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "6 Years to 25 Years"
      },
      "enrollment_count": 127,
      "start_date": "2010-10-08",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01232361"
    },
    {
      "nct_id": "NCT00624195",
      "title": "Clinical Trial of CNS-targeted HAART (CIT2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "FDA Approved Antiretroviral Therapy (see list below)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2007-03",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-04-23",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 5,
      "location_summary": "San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00624195"
    },
    {
      "nct_id": "NCT00440271",
      "title": "SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "tipranavir",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Optimized Background Regimen (OBR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2007-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-27",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 16,
      "location_summary": "Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440271"
    },
    {
      "nct_id": "NCT01276236",
      "title": "Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kaposi's Sarcoma"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2011-03-09",
      "completion_date": "2015-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01276236"
    },
    {
      "nct_id": "NCT00076999",
      "title": "Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "TPV oral solution",
          "type": "DRUG"
        },
        {
          "name": "RTV oral solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 115,
      "start_date": "2003-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-12",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "North Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076999"
    },
    {
      "nct_id": "NCT01923311",
      "title": "Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acquired Immune Deficiency Syndrome (AIDS)",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "EVG",
          "type": "DRUG"
        },
        {
          "name": "Background regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 17 Years"
      },
      "enrollment_count": 31,
      "start_date": "2013-08-26",
      "completion_date": "2017-11-03",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01923311"
    },
    {
      "nct_id": "NCT00146328",
      "title": "Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tipranavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 997,
      "start_date": "2001-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-03-06",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 86,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146328"
    },
    {
      "nct_id": "NCT00056641",
      "title": "Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "tipranavir",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        },
        {
          "name": "saquinavir",
          "type": "DRUG"
        },
        {
          "name": "amprenavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2003-02-18",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-09-02T10:35:01.280Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056641"
    }
  ]
}